University of Texas Health Science Center at Houston

Team assessing if dual-antibody injection prevents COVID-19 illness

Newswise — A combination antibody treatment for preventing COVID-19 illness in individuals who have had sustained exposure to someone with the virus is being studied by researchers at The University of Texas Health Science Center at Houston (UTHealth). The clinical trial is enrolling patients at Harris Health System’s Lyndon B. Johnson Hospital.

The Phase III, randomized, double-blinded, placebo-controlled trial will help researchers determine if the laboratory-made dual-antibody treatment, REGN-COV2, can prevent SARS-CoV-2 infection in individuals who share a home with someone with a confirmed infection.

“If this trial demonstrates that this treatment is effective, it could be used in various settings where exposure risk is heightened, such as health care, airlines, meatpacking factories, nursing homes, and among first responders,” said Roberto C. Arduino, MD, the study’s lead investigator and professor of infectious disease with McGovern Medical School at UTHealth. “It is crucial that we discover treatment options that can not only prevent severe illness, but also stop the spread of COVID-19 within our communities.”

The study team is seeking to enroll asymptomatic individuals who have had at least 48 hours of sustained exposure to a person with a confirmed SARS-CoV-2 infection, known as an index case. Participants must be randomized within 96 hours of the index case’s diagnosis. Trial participants must live in the same household as the index case patient for 29 days during the study.

REGN-COV2 is a combination of two monoclonal (laboratory-made) antibodies that target two different sites of the spike protein found on the surface of SARS-CoV-2, the virus that causes COVID-19.  Antibodies are proteins created by the immune system to fight a pathogen or infection. The targeted surface spike protein gives the virus a crown-like appearance and allows it to attach to and enter cells.

The REGN-COV2 antibody cocktail is a combination of antibodies originally isolated from patients who have recovered from COVID-19 and produced by mice that have been genetically modified to have human immune systems.

The study period will last 32 weeks. On day one of enrollment, patients will receive four subcutaneous injections of either the trial agent or a placebo. This treatment strategy is known as “passive immunization,” and is the current strategy used for tetanus, rabies, hepatitis B, and herpes zoster exposures. Participants will be tested for COVID-19 weekly during the first month they are enrolled.

Co-investigators from McGovern Medical School include Karen J. Vigil, MD, an associate professor of infectious disease and medical director of infection prevention for UT Physicians’ outpatient operations; and Sarah Duong, MD, a general internal medicine physician. Jonatan Gioia, MD, is the program manager.  

Regeneron Pharmaceuticals is sponsoring the clinical trial. For more information, visit ClinicalTrials.gov.




Filters close

Showing results

110 of 3798
Released: 28-Oct-2020 3:20 AM EDT
Risk score predicts prognosis of outpatients with COVID-19
Massachusetts General Hospital

A new artificial intelligence-based score considers multiple factors to predict the prognosis of individual patients with COVID-19 seen at urgent care clinics or emergency departments.

Released: 28-Oct-2020 1:10 AM EDT
Swiss fatalism protects against negative feelings in the pandemic
University of Zurich

Trust or disappointment in government crisis management is an important factor for the general mood, shows a study by the University of Zurich based on surveys in Israel and Switzerland.

Released: 28-Oct-2020 12:05 AM EDT
Low-cost airlines have adapted best to COVID-19
Universitat Oberta De Catalunya (UOC)

The COVID-19 pandemic has caused a dramatic reduction in travel, especially to other countries.

Newswise: Dermatologist Provides Skin Care to People Experiencing Homelessness Amid COVID-19
Released: 27-Oct-2020 5:05 PM EDT
Dermatologist Provides Skin Care to People Experiencing Homelessness Amid COVID-19
American Academy of Dermatology

The American Academy of Dermatology (AAD) named board-certified dermatologist Jennifer Tan, MD, FAAD, a Patient Care Hero for making critical skin care and hygiene items easily accessible to individuals experiencing homelessness during the COVID-19 pandemic.

Released: 27-Oct-2020 5:00 PM EDT
The fact that SARS-CoV-2 virus can or cannot spread through airborne transmission does not render masks "worthless"
Newswise

A video featuring Owen Shroyer originally published by Banned.video went viral on Facebook in late October. The video claims that the U.S. Centers for Disease Control and Prevention (CDC) confirmed SARS-CoV-2, the virus that causes COVID-19, was never airborne, and wearing face masks is unnecessary. This claim is false and inaccurate. The CDC never said the virus could not be airborne. Although the CDC "updated" their guidance on its website to include aerosols among the most common forms of SARS-CoV-2 transmission, experts agree that the virus can spread through water droplets, which masks can act as a physical barrier to stpp the water droplets. There is increasing evidence that suggest airborne transmission may also play a role in the spread of COVID-19.

Newswise: Neutrons chart atomic map of COVID-19’s viral replication mechanism
Released: 27-Oct-2020 3:40 PM EDT
Neutrons chart atomic map of COVID-19’s viral replication mechanism
Oak Ridge National Laboratory

To better understand how the novel coronavirus behaves and how it can be stopped, scientists have completed a three-dimensional map that reveals the location of every atom in an enzyme molecule critical to SARS-CoV-2 reproduction. Researchers at the Department of Energy’s Oak Ridge National Laboratory used neutron scattering to identify key information to improve the effectiveness of drug inhibitors designed to block the virus’s replication mechanism.

access_time Embargo lifts in 2 days
Embargo will expire: 28-Oct-2020 3:10 PM EDT Released to reporters: 27-Oct-2020 2:05 PM EDT

A reporter's PressPass is required to access this story until the embargo expires on 28-Oct-2020 3:10 PM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Released: 27-Oct-2020 12:05 PM EDT
Rush Preparing for COVID-19 Resurgence
Rush University Medical Center

With Chicago and Illinois seeing a surge in cases of COVID-19 and the city and state implementing new restrictions to lessen the spread of the disease, Rush University System for Health is preparing for a resurgence of cases. Rush will continue to diligently prepare and plan its response to the surge to ensure the safety of everyone in Rush hospitals and clinics and within the Rush community.

Released: 27-Oct-2020 11:55 AM EDT
Precaution: Lessons from COVID-19
Singapore University of Technology and Design

Which is more important in the initial phase of a pandemic: taking precautionary actions or responding to its severity? That is the question that researchers from the Singapore University of Technology and Design (SUTD) set out to address in an article published in BioEssays.


Showing results

110 of 3798

close
1.11705